Myoclonic epilepsy
MONDO:0100577A group of epilepsy syndromes in which myoclonic seizures are a prominent feature.
Also known as: myoclonic epilepsy syndrome
23 clinical trials for this condition and its sub-types, 1 tagged with Myoclonic epilepsy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Myoclonic epilepsy
-
Progressive myoclonus epilepsy 5 trials · 12 incl. sub-types
15 sub-types
- MERRF syndrome 5 trials
- Lafora disease 1 trial Sub-types →
- Unverricht-Lundborg syndrome 1 trial
- Neuronal ceroid lipofuscinosis 8 northern epilepsy variant 1 trial
- Action myoclonus-renal failure syndrome 0 trials
- Early-onset Lafora body disease 0 trials
- Epilepsy, progressive myoclonic, 11 0 trials
- Epilepsy, progressive myoclonic, 12 0 trials
- Epilepsy, progressive myoclonic, 1B 0 trials
- Familial encephalopathy with neuroserpin inclusion bodies 0 trials
- Progressive myoclonic epilepsy type 3 0 trials
- Progressive myoclonic epilepsy type 6 0 trials
- Progressive myoclonic epilepsy type 7 0 trials
- Progressive myoclonic epilepsy type 8 0 trials
- Progressive myoclonic epilepsy type 9 0 trials
-
Juvenile myoclonic epilepsy 3 trials
1 sub-type
- Myoclonic epilepsy, juvenile, 2 0 trials
-
Epilepsy, familial adult myoclonic 0 trials
8 sub-types
- Benign adult familial myoclonic epilepsy 0 trials
- Epilepsy, familial adult myoclonic, 1 0 trials
- Epilepsy, familial adult myoclonic, 2 0 trials
- Epilepsy, familial adult myoclonic, 3 0 trials
- Epilepsy, familial adult myoclonic, 4 0 trials
- Epilepsy, familial adult myoclonic, 5 0 trials
- Epilepsy, familial adult myoclonic, 6 0 trials
- Epilepsy, familial adult myoclonic, 7 0 trials
-
Myoclonic epilepsy in infancy 0 trials
-
Myoclonic epilepsy, Hartung type 0 trials
Most studied deeper sub-types
-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Routine EEGs may hold hidden clues to childhood epilepsy — a new analysis method is put to the test
Diagnosis CompletedThis study is testing whether a computer tool called BioEP can detect signs of seizure susceptibility in standard EEG recordings from children with epilepsy. Researchers will analyze past EEGs from 530 children aged 2 to 18 who already have an epilepsy diagnosis. The goal is to s…
Sponsor: Neuronostics Ltd • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
Traffic-light labels on menus: do they nudge us to eat better?
Knowledge-focused CompletedThis study tested whether adding Nutri-score labels (A to E ratings) to restaurant menus, alongside calorie information, helps people pick healthier meals. Over 600 adults in Liverpool ordered from a menu with either calorie info alone or calorie info plus Nutri-score labels. Res…
Sponsor: University of Liverpool • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC